Trifluridine/tipiracil + bevacizumab
Checked 2026-09-09
Refractory metastatic colorectal cancer after two lines
One cycle
every 28 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Trifluridine/tipiracil Cytotoxic chemotherapy (oral nucleoside) | 35 mg/m² twice daily | Oral | D1, 2, 3, 4, 5, 8, 9, 10, 11, 12 | |
Bevacizumab Monoclonal antibody (anti-VEGF) | 5 mg/kg | IV | D1, 15 |
Cycles
until progression
28-day cycle
Emetogenicity
Low (10-30%)
G-CSF
Not routine
Used in
Trials
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
mFOLFOX6
Adjuvant stage III colon (6 months) or metastatic colorectal and upper GI first line
every 14 days × 12
CAPOX
Adjuvant stage III colon (3 or 6 months), rectal total neoadjuvant therapy, metastatic first line
every 21 days × 4
FOLFIRI
Metastatic colorectal first or second line (with bevacizumab, aflibercept, ramucirumab or an anti-EGFR antibody)
every 14 days
Pembrolizumab monotherapy
Adjuvant melanoma stage IIB-IV (1 year); PD-L1 TPS 50% or above NSCLC; MSI-high tumours; recurrent head and neck (CPS 1 or above)
every 21 days